My NCBISign In

Display Settings:

Format

Send to:

Choose Destination

    Am J Psychiatry. 2003 May;160(5):993-6.

    Placental passage of antidepressant medications.

    Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D.

    Mood Disorders Research Program, UCLA Neuropsychiatric Institute and Hospital, University of California-Los Angeles, 300 Medical Plaza, Suite 2345, Los Angeles, CA 90095, USA. vhendric@ucla.edu

    OBJECTIVE: This study determined the placental transfer of antidepressants and their metabolites. METHOD: A total of 38 pregnant women taking citalopram, fluoxetine, paroxetine, or sertraline participated. Maternal and umbilical cord blood samples were obtained to determine antidepressant and metabolite concentrations. RESULTS: Antidepressant and metabolite concentrations were detectable in 86.8% of umbilical cord samples. The mean ratios of umbilical cord to maternal serum concentrations ranged from 0.29 to 0.89. The lowest ratios were for sertraline and paroxetine; the highest were for citalopram and fluoxetine. Maternal doses of sertraline and fluoxetine correlated with umbilical cord concentrations of these medications. CONCLUSIONS: Umbilical cord concentrations of antidepressants and their metabolites were almost invariably lower than corresponding maternal concentrations. Maternal doses predicted umbilical concentrations of fluoxetine and sertraline. Mean umbilical cord to maternal serum ratios were significantly lower for sertraline than fluoxetine, suggesting that sertraline may produce less fetal medication exposure than fluoxetine near delivery.

    PMID: 12727706 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read
    Write to the Help Desk